AERI - Aerie Pharmaceuticals, Inc.
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Currency in USD
Valuation measures
| Market cap (intra-day) 5 | 920.18M |
| Enterprise value 3 | 757.13M |
| Trailing P/E | N/A |
| Forward P/E 1 | -8.56 |
| PEG ratio (5-yr expected) 1 | N/A |
| Price/sales (ttm) | 15.42 |
| Price/book (mrq) | 4.37 |
| Enterprise value/revenue 3 | 12.69 |
| Enterprise value/EBITDA 6 | -4.21 |
Trading information
Stock price history
| Beta (3Y monthly) | 0.45 |
| 52-week change 3 | -51.25% |
| S&P500 52-week change 3 | 18.39% |
| 52-week high 3 | 50.10 |
| 52-week low 3 | 17.15 |
| 50-day moving average 3 | 20.19 |
| 200-day moving average 3 | 24.41 |
Share statistics
| Avg vol (3-month) 3 | 1.3M |
| Avg vol (10-day) 3 | 853.02k |
| Shares outstanding 5 | 46.32M |
| Float | 35.46M |
| % held by insiders 1 | 1.84% |
| % held by institutions 1 | 112.53% |
| Shares short (15 Nov 2019) 4 | 14.76M |
| Short ratio (15 Nov 2019) 4 | 11.26 |
| Short % of float (15 Nov 2019) 4 | 37.94% |
| Short % of shares outstanding (15 Nov 2019) 4 | 31.86% |
| Shares short (prior month 15 Oct 2019) 4 | 13.89M |
Dividends & splits
| Forward annual dividend rate 4 | N/A |
| Forward annual dividend yield 4 | N/A |
| Trailing annual dividend rate 3 | N/A |
| Trailing annual dividend yield 3 | N/A |
| 5-year average dividend yield 4 | N/A |
| Payout ratio 4 | 0.00% |
| Dividend date 3 | N/A |
| Ex-dividend date 4 | N/A |
| Last split factor (new per old) 2 | N/A |
| Last split date 3 | N/A |
Financial highlights
Fiscal year
| Fiscal year ends | 31 Dec 2018 |
| Most-recent quarter (mrq) | 30 Sep 2019 |
Profitability
| Profit margin | 0.00% |
| Operating margin (ttm) | -317.45% |
Management effectiveness
| Return on assets (ttm) | -30.04% |
| Return on equity (ttm) | -82.04% |
Income statement
| Revenue (ttm) | 59.69M |
| Revenue per share (ttm) | 1.32 |
| Quarterly revenue growth (yoy) | 154.00% |
| Gross profit (ttm) | -3M |
| EBITDA | -179.66M |
| Net income avi to common (ttm) | -195.98M |
| Diluted EPS (ttm) | -4.32 |
| Quarterly earnings growth (yoy) | N/A |
Balance sheet
| Total cash (mrq) | 340.78M |
| Total cash per share (mrq) | 7.36 |
| Total debt (mrq) | 201.59M |
| Total debt/equity (mrq) | 96.36 |
| Current ratio (mrq) | 5.43 |
| Book value per share (mrq) | 4.55 |
Cash flow statement
| Operating cash flow (ttm) | -154.82M |
| Levered free cash flow (ttm) | -92.14M |